Affluent Medical Reports Promising Epygon Valve Performance and Recognition

Affluent Medical announced significant clinical advancements for its Epygon mitral valve, emphasizing exceptional performance outcomes at the one-year mark and increased acknowledgment within the cardiologist community. The Epygon valve, innovatively designed to replicate the natural dynamics and anatomy of the human heart's mitral valve, has shown promising results in transcatheter mitral valve replacement.

The first human implantation of Epygon, detailed in the Journal of the American College of Cardiology: Cardiovascular Interventions, marks a critical milestone. Conducted by Prof. Stefano Salizzoni and his team in Italy, the procedure and subsequent six-month follow-up underscored the valve's reliable performance. Moreover, a recent one-year follow-up through transesophageal echocardiogram reaffirmed its effectiveness, presenting no signs of mitral regurgitation or paravalvular leak.

Reflecting the medical community's growing trust in Epygon, a survey revealed 70% of interventional cardiologists would recommend the valve based on its hemodynamic benefits. Epygon's unique approach aims to enhance left ventricle function and improve patient outcomes by emulating the native valve's flow dynamics closely. This breakthrough could significantly impact the treatment of mitral valve regurgitation, a condition affecting millions worldwide. Currently, the market for mitral valve repair in the U.S.-Europe is valued at $1.5 billion, with projections of steady growth.